Seattle Genetics
Seattle Genetics reaches milestone in antibody-drug conjugate collaboration with CuraGen
Published in Biotech Law Weekly, July 21st, 2006
The milestone was achieved upon CuraGen's initiation of a phase 1 clinical trial with its lead ADC, CR011-vcMMAE, for the treatment of metastatic melanoma.
ADCs utilize the targeting ability of monoclonal antibodies to deliver cell-killing payloads to tumor cells. Seattle Genetics' ADC technology employs synthetic, highly potent drugs, such as monomethyl auristatin E (MMAE), which are attached to antibodies through proprietary...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
Source: Biotech Law Weekly (2006-07-21)
More Articles from Biotech Law Weekly
- Alnylam
Alnylam reports positive outcome in European proceedings on Kreutzer-Limmer I patent - Clarient
Clarient signs agreement to purchase assets of Trestle Holdings, Inc. - Cobalis
Cobalis' E.U. patent for PreHistin becomes effective - Fitch Ratings
Fitch revises Schering-Plough Corp.'s Rating Outlook to Stable, affirms 'A-/F2' - Groningen University, Netherlands
More patients switch to another proton pump inhibitor after omeprazole patent expiry - Healthcare Costs
A new survey released finds that Medicare prescription drug plans are paying pharmacists promptly - More from this issue of Biotech Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
